CAJ | 학술논문

临床前研究表明降糖药二甲双胍对乳腺癌有抗肿瘤作用,能降低糖尿病患者乳腺癌发病风险和死亡风险,也能提高乳腺癌患者新辅助化疗后病理完全缓解率.体内外实验表明二甲双胍有效抑制各种乳腺癌细胞和移植瘤,并和化疗药物、HER2靶向药物、新型抗肿瘤药物有良好协同作用.主要分子机制包括全身性下调胰岛素及相关信号通路、肿瘤细胞内激活LKBI/AMPK、抑制下游mTOR通路等.目前各国开展了多个临床试验评估二甲双胍在乳腺癌防治中的应用价值.
림상전연구표명강당약이갑쌍고대유선암유항종류작용,능강저당뇨병환자유선암발병풍험화사망풍험,야능제고유선암환자신보조화료후병리완전완해솔.체내외실험표명이갑쌍고유효억제각충유선암세포화이식류,병화화료약물、HER2파향약물、신형항종류약물유량호협동작용.주요분자궤제포괄전신성하조이도소급상관신호통로、종류세포내격활LKBI/AMPK、억제하유mTOR통로등.목전각국개전료다개림상시험평고이갑쌍고재유선암방치중적응용개치.
Recent preclinical data have demonstrated that antidiabetic drug metformin can act as an anticancer agent for breast cancer.Epidemiologic evidences show that metformin decreases the incidence of breast cancer and cancer-related mortality in diabetic patients.The metformin treatment also increases complete pathological tumor response rates following neoadjuvant chemotherapy for breast cancer patients.Metformin also displays significant growth inhibitory effects in most types of breast cancer cell lines and tumor xenogra-fts in mice.Preclinical data also shows metformin combined with chemotherapy drugs or HER2-targeted drugs or new anticancer drugs has synergic anti-cancer effect.Reduction of the insulin/insulin-like growth factor signaling pathway in body and activation of LKB1/AMPK and inhibition of downstream mTOR pathway in tumor cells have been found to play the most important role in anti-cancer effect of metformin.Currently,a number of clinical trials are underway in breast cancer patients to evaluate the effective use value of metformin as a cancer therapy